VelosBio   Report issue

For profit Phase 2
Founded: San Diego CA United States (2017)
Status: Acquired by Merck (2020)

Organization Overview

First Clinical Trial
2019
NCT03833180
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

VelosBio Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

vls-101 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Burkitt Lymphoma (Phase 1)

Leukemia (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Lymphoid (Phase 1)

Lymphoma (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Lymphoma, Mantle-Cell (Phase 1)

Lymphoma, T-Cell (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Triple Negative Breast Neoplasms (Phase 2)

Waldenstrom Macroglobulinemia (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1